Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Autolus Therapeutics Announces Publication of Data from the FELIX study of obe-cel in r/r Adult B-ALL Patients in The New England Journal of Medicine High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity:...

Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates